(ClinGenuity is)...producing unmatched efficiencies in creating regulatory documents, reducing time to get important medicines to patients in need faster and cheaper, saving lives and potentially billions of dollars across the industry.
Cincinnati, Ohio (PRWEB) June 03, 2014
ClinGenuity of Cincinnati announces it has been named a Global Preferred Vendor for a Top 5 pharmaceutical client.
Additionally, the client has opted to simultaneously extend the standing two-year automated Clinical Study Reports (CSR) deal for an additional 12 months.
The combination of ClinGenuity’s expert medical writing staff and the industry’s only artificial intelligence (AI) technology is proving to be an enticing proposition to major pharmaceutical companies seeking to expedite drug development while reducing costs, said ClinGenuity founder and CEO Keith Kleeman.
With more than 100 medical writers comprising an average of almost 10 years of experience and 80 percent with advanced degrees, medical writing bench ranks as one of the most experienced, seasoned, knowledgeable and sizeable in the industry.
ClinGenuity is the first and only company to utilize AI technology to expedite drug development.
The ClinGenuity AI engine understands documents and the way they are written. The system automatically analyzes a company’s specific templates and style guides and builds a platform customized to specific writing and reporting conventions. It then analyzes past documents and understands how best to build new CSRs, protocols, patient narratives, submission documents, and others-- quickly, accurately, and consistently.
One tool in the full suite offering, the ClinGenuity Report Writer, automatically drafts fully-compliant clinical study reports in under an hour, a process that can manually take up to eight weeks. The advancement results in a significant reduction in reporting time and resource effort for each clinical study, and time and financial savings for a drug to come to market.
“Our technology-enabled full suite service offering is producing unmatched efficiencies in creating regulatory documents, reducing the time it takes to get important medicines to patients in need faster and cheaper, saving lives and potentially billions of dollars across the industry,” said Kleeman. “And major pharmaceutical clients are taking note.”
Technology holds one of the last and most promising pieces to increase drug development efficiency and shrink the time it takes to get much-needed new drugs to market; however, technology alone can be problematic.
“The key,” said Kleeman, “is offering a complete solution of cutting-edge technology with industry leading service.”
“We are excited by the recent developments and of once again being designated a Global Preferred Vendor for all medical writing services for our major pharmaceutical partner,” he added. “We are likewise extremely pleased that our client is seeing immediate and tangible value from our ClinGenuity Report Writer technology and has decided to further invest in our relationship by extending the technology deal by another year. They and our other clients are pleased to realize significant savings after nearly two years of using the ClinGenuity technology. That is our ultimate goal with all clients.”
For more information on ClinGenuity, go to http://www.clingenuity.com or call (513) 239-6918.
# # #
Contact: Keith Kleeman
Email: kkleeman(at)clingenuity(dot)com
Phone: 513. 239-6918
About ClinGenuity:
ClinGenuity, a Cincinnati-based medical writing company using expert medical writers assigned to each project according to expertise, has the only artificially-intelligent tool in the pharmaceutical industry. ClinGenuity increases new drug and medical device development efficiencies to help reduce development cycle times and costs.
